治験用品市場:2027 年の世界予測

出版:MarketsandMarkets(マーケッツアンドマーケッツ) 出版年月:2022年10月

治験用品市場:サービス (製造、包装、ロジスティクス)、フェーズ (I ~ IV)、タイプ (低分子、生物製剤)、治療領域 (腫瘍学、CVD、感染症、免疫学)、エンドユーザー (製薬、バイオテクノロジー、CRO) – 2027 年の世界予測
Clinical Trial Supplies Market by Services (Manufacturing, Packaging, Logistics), Phases (I to IV), Type (Small Molecules, Biologics), Therapeutic Areas (Oncology, CVD, Infectious, Immunology), End User (Pharma, Biotech, CROs) – Global Forecast 2027

ページ数 254
図表数 285
種別 英文調査報告書
価格

レポート目次    お問合せ・ご注文    価格・納期について

無料サンプル

MarketsandMarkets(マーケッツアンドマーケッツ)「治験用品市場:サービス (製造、包装、ロジスティクス)、フェーズ (I ~ IV)、タイプ (低分子、生物製剤)、治療領域 (腫瘍学、CVD、感染症、免疫学)、エンドユーザー (製薬、バイオテクノロジー、CRO) – 2027 年の世界予測 – Clinical Trial Supplies Market by Services (Manufacturing, Packaging, Logistics), Phases (I to IV), Type (Small Molecules, Biologics), Therapeutic Areas (Oncology, CVD, Infectious, Immunology), End User (Pharma, Biotech, CROs) – Global Forecast 2027」は世界の治験(臨床試験)用品市場を調査し、主要セグメント毎に行った分析・予測結果を提供します。

The Global Clinical Trial Supplies market is projected to reach USD 5.7 billion by 2027 from USD 3.6 billion in 2022, at a CAGR of 9.7% during the forecast period of 2022 to 2027. Factors such a as globalization of clinical trials and growing R&D expenditure in pharmaceutical and biopharmaceutical companies are driving the market.

Clinical Trial Supplies Market - MarketsandMarkets

“The logistics and distribution segment accounted for the highest growth rate in the clinical trial supplies market, by service, during the forecast period”

In 2021, the logistics & distribution services segment accounted for the largest share of the clinical trial supplies market. Factors such as the globalization of clinical trials, expertise of supply companies in terms of therapeutic areas and geographical reach and the increasing number of trials involving temperature-sensitive products are driving the market.

“Oncology segment accounted for the largest share of the therapeutic area segment”
On the basis of therapeutic area, the clinical trial supplies market is divided into oncology, cardiovascular diseases, digestive disorders, infectious diseases, CNS & mental disorders, metabolic disorders, immunology, blood disorders, and other therapeutic areas (respiratory disorders, dermatological disorders, rare diseases, ENT diseases, Nephrology). In 2021, Oncology is the largest segment in this market. Factors such as increasing number of research studies on cancer therapeutics and the emerging companies and the high incidence and prevalence of cancer is driving the market.

“Asia Pacific: The fastest-growing region in the clinical trial supplies market”
On the basis of region, the clinical trial supplies market is segmented into North America, Europe, Asia Pacific, Rest of world. During the forecast period, the Asia Pacific market is expected to be the fastest-growing regional segment. Factors such as growing investments and expansions by key companies in countries such as China, India, and South Korea.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 80% and Demand Side 20%
• By Designation: C-level – 20%, Executives – 25%, and Managers – 55%
• By Region: Asia Pacific -50%, North America -30%, Europe -10%, RoW -10%

北米の治験用品市場 - マーケッツアンドマーケッツ
Lists of Companies Profiled in the Report:
• Thermo Fisher (US)
• Catalent, Inc. (US)
• Parexel (US)
• Eurofins (France)
• Piramal Pharma Solutions (India)
• Almac Group (UK)
• PCI Pharma Services (US)
• PRA Health Sciences (US)
• Biocair (UK), Eurofins (France)
• Marken (US)
• Infosys (India)
• Liveo Research (India)
• Capsugel (a Lonza Group company) (Switzerland)
• KLIFO A/S (Denmark)
• Clinigen (UK)
• Ancillare (US)
• N-SIDE (Belgium)
• ADAllen (UK)
• Durbin (UK)
• Recipharm (Sweden)
• OCT Group LLC. (Latvia)
• Corex Logistics (Ireland)
• Acnos Pharma GMBH (Germany)
• Clinical Services International (UK)
• Movianto (Ireland)

Research Coverage:
This report provides a detailed picture of the clinical trial supplies market. It aims at estimating the size and future growth potential of the market across different segments such as the service, end user, phases, therapeutic areas, type and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall clinical trial supplies market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, trends, and opportunities.


目次

1 INTRODUCTION 32
1.1 STUDY OBJECTIVES 32
1.2 MARKET DEFINITION 32
1.2.1 INCLUSIONS AND EXCLUSIONS 33
1.3 MARKET SCOPE 34
1.3.1 MARKETS COVERED 34
FIGURE 1 CLINICAL TRIAL SUPPLIES MARKET: GEOGRAPHIC SCOPE 35
1.3.2 YEARS CONSIDERED 35
1.4 CURRENCY 36
1.5 LIMITATIONS 36
1.6 STAKEHOLDERS 36
1.7 SUMMARY OF CHANGES 36

2 RESEARCH METHODOLOGY 38

2.1 RESEARCH APPROACH 38
FIGURE 2 RESEARCH DESIGN 38
2.1.1 SECONDARY DATA 39
2.1.2 PRIMARY DATA 40
FIGURE 3 BREAKDOWN OF PRIMARIES: CLINICAL TRIAL SUPPLIES MARKET 40
2.2 MARKET DATA ESTIMATION AND TRIANGULATION 41
FIGURE 4 DATA TRIANGULATION METHODOLOGY 41
2.3 MARKET ESTIMATION METHODOLOGY 42
FIGURE 5 MARKET SIZE ESTIMATION APPROACH: COMPANY REVENUE ANALYSIS 42
FIGURE 6 CLINICAL TRIAL SUPPLIES MARKET: FINAL MARKET SIZE (USD BILLION) 43
2.4 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST 43
FIGURE 7 GROWTH RATE ASSUMPTION BASED ON MARKET DYNAMICS 43
FIGURE 8 FINAL CAGR PROJECTIONS (2022−2027) 44
2.5 INSIGHTS FROM PRIMARIES 44
FIGURE 9 MARKET VALIDATION FROM PRIMARY EXPERTS 44
2.6 RESEARCH ASSUMPTIONS 45
2.7 RISK ASSESSMENT 45
TABLE 1 RISK ASSESSMENT 45

3 EXECUTIVE SUMMARY 46

FIGURE 10 CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION) 46
FIGURE 11 CLINICAL TRIAL SUPPLIES MARKET SHARE, BY SERVICE, 2021 47
FIGURE 12 CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2022 VS. 2027 (USD MILLION) 47
FIGURE 13 CLINICAL TRIAL SUPPLIES MARKET SHARE, BY THERAPEUTIC AREA, 2021 48
FIGURE 14 CLINICAL TRIAL SUPPLIES MARKET SHARE, BY END USER, 2021 48
FIGURE 15 GEOGRAPHICAL SNAPSHOT OF CLINICAL TRIAL SUPPLIES MARKET 49

4 PREMIUM INSIGHTS 50

4.1 CLINICAL TRIAL SUPPLIES MARKET OVERVIEW 50
FIGURE 16 INCREASING R&D EXPENDITURE OF PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES TO DRIVE MARKET 50
4.2 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET SHARE, BY TYPE AND COUNTRY (2021) 51
FIGURE 17 SMALL-MOLECULE DRUGS ACCOUNTED FOR LARGEST SHARE OF CLINICAL TRIAL SUPPLIES MARKET IN NORTH AMERICA 51
4.3 CLINICAL TRIAL SUPPLIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 52
FIGURE 18 ASIA PACIFIC TO REGISTER HIGHEST GROWTH IN CLINICAL TRIAL SUPPLIES MARKET FROM 2022 TO 2027 52

5 MARKET OVERVIEW 53

5.1 INTRODUCTION 53
5.2 MARKET DYNAMICS 53
FIGURE 19 CLINICAL TRIAL SUPPLIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 53
5.3 IMPACT ANALYSIS 54
5.3.1 DRIVERS 54
5.3.1.1 Increasing R&D expenditure of pharmaceutical and biopharmaceutical companies 54
5.3.1.2 Increasing number of registered clinical trials 55
FIGURE 20 REGISTERED CLINICAL STUDIES, 2011–2022 55
5.3.1.3 Increasing decentralization of clinical trials 56
5.3.2 RESTRAINTS 56
5.3.2.1 High cost of drug development 56
5.3.3 OPPORTUNITIES 56
5.3.3.1 Emerging markets 56
5.3.4 CHALLENGES 57
5.3.4.1 High cost of clinical trials 57
5.4 RANGES/SCENARIOS 58
FIGURE 21 SCENARIOS OF CLINICAL TRIAL SUPPLIES MARKET 58
5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 59
5.6 VALUE CHAIN ANALYSIS 59
FIGURE 22 VALUE CHAIN ANALYSIS OF CLINICAL TRIAL SUPPLIES MARKET 59
5.7 ECOSYSTEM/MARKET MAP 60
5.8 SUPPLY CHAIN 60
5.9 PORTER’S FIVE FORCES ANALYSIS 61
TABLE 2 PORTER’S FIVE FORCES ANALYSIS: CLINICAL TRIAL SUPPLIES MARKET 61
5.9.1 THREAT OF NEW ENTRANTS 61
5.9.2 THREAT OF SUBSTITUTES 62
5.9.3 BARGAINING POWER OF SUPPLIERS 62
5.9.4 BARGAINING POWER OF BUYERS 62
5.9.5 DEGREE OF COMPETITION 62
5.10 REGULATORY LANDSCAPE 63
5.10.1 INTRODUCTION 63
5.11 KEY CONFERENCES AND EVENTS IN 2022–2023 66
TABLE 3 CLINICAL TRIAL SUPPLIES MARKET: DETAILED LIST OF CONFERENCES AND EVENTS 66
5.12 TECHNOLOGY ANALYSIS 67
5.12.1 INTERACTIVE RESPONSE TECHNOLOGY (IRT) 67
5.13 PATENT ANALYSIS 68
FIGURE 23 TOP PATENTS IN CLINICAL TRIAL SUPPLIES MARKET 68

6 CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE 69

6.1 INTRODUCTION 70
TABLE 4 CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020–2027 (USD MILLION) 70
6.2 LOGISTICS AND DISTRIBUTION 70
6.2.1 EVOLVING TREATMENT PROTOCOLS AND DATA SECURITY CHALLENGES TO DRIVE DEMAND FOR LOGISTICS AND DISTRIBUTION SERVICES 70
TABLE 5 CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS AND DISTRIBUTION SERVICES, BY REGION, 2020–2027 (USD MILLION) 71
TABLE 6 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS AND DISTRIBUTION SERVICES, BY COUNTRY, 2020–2027 (USD MILLION) 71
TABLE 7 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS AND DISTRIBUTION SERVICES, BY COUNTRY, 2020–2027 (USD MILLION) 71
TABLE 8 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS AND DISTRIBUTION SERVICES, BY COUNTRY, 2020–2027 (USD MILLION) 72
6.3 STORAGE AND RETENTION 72
6.3.1 GROWING DEMAND FOR DIRECT-TO-PATIENT AND DIRECT-TO-SITE SERVICES TO DRIVE GROWTH 72
TABLE 9 CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE AND RETENTION SERVICES, BY REGION, 2020–2027 (USD MILLION) 72
TABLE 10 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE AND RETENTION SERVICES, BY COUNTRY, 2020–2027 (USD MILLION) 73
TABLE 11 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE AND RETENTION SERVICES, BY COUNTRY, 2020–2027 (USD MILLION) 73
TABLE 12 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE AND RETENTION SERVICES, BY COUNTRY, 2020–2027 (USD MILLION) 74
6.4 PACKAGING, LABELING, AND BLINDING 74
6.4.1 RISING DEMAND FOR ADVANCED PACKAGING TO DRIVE MARKET 74
TABLE 13 CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY REGION, 2020–2027 (USD MILLION) 75
TABLE 14 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY COUNTRY, 2020–2027 (USD MILLION) 75
TABLE 15 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY COUNTRY, 2020–2027 (USD MILLION) 75
TABLE 16 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY COUNTRY, 2020–2027 (USD MILLION) 76
6.5 MANUFACTURING 76
6.5.1 GROWING FOCUS OF COMPANIES ON INCREASING THEIR MANUFACTURING CAPACITIES TO DRIVE MARKET 76
TABLE 17 CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY REGION, 2020–2027 (USD MILLION) 77
TABLE 18 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2020–2027 (USD MILLION) 77
TABLE 19 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2020–2027 (USD MILLION) 77
TABLE 20 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2020–2027 (USD MILLION) 78
6.6 COMPARATOR SOURCING 78
6.6.1 INTENSE MARKET COMPETITION, REGULATORY PRESSURE, AND RISING NUMBER OF CLINICAL TRIALS IN EMERGING COUNTRIES TO DRIVE GROWTH 78
TABLE 21 CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY REGION, 2020–2027 (USD MILLION) 79
TABLE 22 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2020–2027 (USD MILLION) 79
TABLE 23 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2020–2027 (USD MILLION) 79
TABLE 24 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2020–2027 (USD MILLION) 80
6.7 OTHER SERVICES 80
TABLE 25 CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES, BY REGION, 2020–2027 (USD MILLION) 81
TABLE 26 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES, BY COUNTRY, 2020–2027 (USD MILLION) 81
TABLE 27 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES, BY COUNTRY, 2020–2027 (USD MILLION) 81
TABLE 28 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES, BY COUNTRY, 2020–2027 (USD MILLION) 82

7 CLINICAL TRIAL SUPPLIES MARKET, BY PHASE 83

7.1 INTRODUCTION 84
TABLE 29 CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2020–2027 (USD MILLION) 84
7.2 PHASE III 84
7.2.1 PHASE III TRIALS INVOLVE LARGE PATIENT POPULATION 84
TABLE 30 CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III CLINICAL TRIALS, BY REGION, 2020–2027 (USD MILLION) 85
TABLE 31 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III CLINICAL TRIALS, BY COUNTRY, 2020–2027 (USD MILLION) 85
TABLE 32 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III CLINICAL TRIALS, BY COUNTRY, 2020–2027 (USD MILLION) 85
TABLE 33 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III CLINICAL TRIALS, BY COUNTRY, 2020–2027 (USD MILLION) 86
7.3 PHASE II 86
7.3.1 PHASE II CLINICAL TRIALS HELP IN UNDERSTANDING EFFECTIVENESS OF DRUG AND FURTHER EVALUATING ITS SAFETY 86
TABLE 34 CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II CLINICAL TRIALS, BY REGION, 2020–2027 (USD MILLION) 87
TABLE 35 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II CLINICAL TRIALS, BY COUNTRY, 2020–2027 (USD MILLION) 87
TABLE 36 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II CLINICAL TRIALS, BY COUNTRY, 2020–2027 (USD MILLION) 87
TABLE 37 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II CLINICAL TRIALS, BY COUNTRY, 2020–2027 (USD MILLION) 88
7.4 PHASE I 88
7.4.1 QUALITY OF CLINICAL TRIAL SUPPLIES AND LOGISTICS PLAY VITAL ROLE IN PHASE I CLINICAL TRIALS 88
TABLE 38 CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I CLINICAL TRIALS, BY REGION, 2020–2027 (USD MILLION) 88
TABLE 39 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I CLINICAL TRIALS, BY COUNTRY, 2020–2027 (USD MILLION) 89
TABLE 40 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I CLINICAL TRIALS, BY COUNTRY, 2020–2027 (USD MILLION) 89
TABLE 41 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I CLINICAL TRIALS, BY COUNTRY, 2020–2027 (USD MILLION) 90
7.5 PHASE IV 90
7.5.1 PHASE IV STUDIES ALLOW RESEARCHERS TO OBSERVE LONG-TERM EFFECTS OF PARTICULAR DRUGS IN LARGER POOL OF PATIENTS 90
TABLE 42 CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV CLINICAL TRIALS, BY REGION, 2020–2027 (USD MILLION) 90
TABLE 43 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV CLINICAL TRIALS, BY COUNTRY, 2020–2027 (USD MILLION) 91
TABLE 44 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV CLINICAL TRIALS, BY COUNTRY, 2020–2027 (USD MILLION) 91
TABLE 45 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV CLINICAL TRIALS, BY COUNTRY, 2020–2027 (USD MILLION) 92
7.6 BA/BE STUDIES 92
7.6.1 PATENT EXPIRATION OF DRUGS TO INCREASE DEMAND FOR BA/BE STUDIES 92
TABLE 46 CLINICAL TRIAL SUPPLIES MARKET FOR BA/BE STUDIES, BY REGION, 2020–2027 (USD MILLION) 92
TABLE 47 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR BA/BE STUDIES, BY COUNTRY, 2020–2027 (USD MILLION) 93
TABLE 48 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR BA/BE STUDIES, BY COUNTRY, 2020–2027 (USD MILLION) 93
TABLE 49 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR BA/BE STUDIES, BY COUNTRY, 2020–2027 (USD MILLION) 94

8 CLINICAL TRIAL SUPPLIES MARKET, BY TYPE 95

8.1 INTRODUCTION 96
TABLE 50 CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 96
8.2 SMALL-MOLECULE DRUGS 96
8.2.1 LOW COST OF DEVELOPING SMALL-MOLECULE DRUGS TO DRIVE MARKET 96
TABLE 51 CLINICAL TRIAL SUPPLIES MARKET FOR SMALL-MOLECULE DRUGS, BY REGION, 2020–2027 (USD MILLION) 97
TABLE 52 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2020–2027 (USD MILLION) 97
TABLE 53 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2020–2027 (USD MILLION) 97
TABLE 54 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2020–2027 (USD MILLION) 98
8.3 BIOLOGIC DRUGS 98
8.3.1 BIOLOGIC DRUGS HAVE RELATIVELY LOW RATE OF ATTRITION COMPARED TO SMALL-MOLECULE DRUGS 98
TABLE 55 CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGIC DRUGS, BY REGION, 2020–2027 (USD MILLION) 99
TABLE 56 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGIC DRUGS, BY COUNTRY, 2020–2027 (USD MILLION) 99
TABLE 57 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGIC DRUGS, BY COUNTRY, 2020–2027 (USD MILLION) 99
TABLE 58 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGIC DRUGS, BY COUNTRY, 2020–2027 (USD MILLION) 100
8.4 MEDICAL DEVICES 100
8.4.1 INCREASING NUMBER OF TRIALS FOR MEDICAL DEVICES TO DRIVE MARKET 100
TABLE 59 CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES, BY REGION, 2020–2027 (USD MILLION) 100
TABLE 60 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2020–2027 (USD MILLION) 101
TABLE 61 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2020–2027 (USD MILLION) 101
TABLE 62 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2020–2027 (USD MILLION) 102

9 CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA 103

9.1 INTRODUCTION 104
TABLE 63 CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION) 104
9.2 ONCOLOGY 104
9.2.1 GROWING STUDIES ON CANCER THERAPEUTICS TO DRIVE MARKET 104
TABLE 64 CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY REGION, 2020–2027 (USD MILLION) 105
TABLE 65 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 105
TABLE 66 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 105
TABLE 67 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 106
9.3 CNS AND MENTAL DISORDERS 106
9.3.1 INCREASING CASES OF MENTAL DISORDERS TO DRIVE MARKET 106
TABLE 68 CLINICAL TRIAL SUPPLIES MARKET FOR CNS AND MENTAL DISORDERS, BY REGION, 2020–2027 (USD MILLION) 107
TABLE 69 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR CNS AND MENTAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 107
TABLE 70 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR CNS AND MENTAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 107
TABLE 71 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR CNS AND MENTAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 108
9.4 CARDIOVASCULAR DISEASES 108
9.4.1 GROWING INVESTMENTS BY PHARMACEUTICAL COMPANIES FOR CVD RESEARCH TO DRIVE GROWTH 108
TABLE 72 CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2020–2027 (USD MILLION) 108
TABLE 73 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 109
TABLE 74 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 109
TABLE 75 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 110
9.5 DIGESTIVE DISORDERS 110
9.5.1 INCREASING R&D FOR DEVELOPMENT OF EFFECTIVE DRUGS TO DRIVE MARKET 110
TABLE 76 CLINICAL TRIAL SUPPLIES MARKET FOR DIGESTIVE DISORDERS, BY REGION, 2020–2027 (USD MILLION) 111
TABLE 77 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR DIGESTIVE DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 111
TABLE 78 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR DIGESTIVE DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 111
TABLE 79 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR DIGESTIVE DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 112
9.6 INFECTIOUS DISEASES 112
9.6.1 EMERGENCE OF NEW INFECTIONS SUCH AS EBOLA, ZIKA, AND COVID-19 ACCELERATED EFFORTS TO DEVELOP NEW DRUGS 112
TABLE 80 CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2020–2027 (USD MILLION) 113
TABLE 81 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 113
TABLE 82 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 113
TABLE 83 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 114
9.7 METABOLIC DISORDERS 114
9.7.1 INCREASING PREVALENCE OF DIABETES AND OTHER METABOLIC DISORDERS TO DRIVE GROWTH 114
TABLE 84 CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS, BY REGION, 2020–2027 (USD MILLION) 114
TABLE 85 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 115
TABLE 86 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 115
TABLE 87 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 116
9.8 BLOOD DISORDERS 116
9.8.1 GROWTH IN NUMBER OF HEMOPHILIA PATIENTS TO BOOST PRODUCTION OF MACROMOLECULES AND RECOMBINANT FACTORS 116
TABLE 88 CLINICAL TRIAL SUPPLIES MARKET FOR BLOOD DISORDERS, BY REGION, 2020–2027 (USD MILLION) 116
TABLE 89 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR BLOOD DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 117
TABLE 90 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR BLOOD DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 117
TABLE 91 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR BLOOD DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 118
9.9 IMMUNOLOGY 118
9.9.1 CONTINUOUS GROWTH IN CLINICAL STUDIES FOR IMMUNE SYSTEM DISEASES TO FUEL NEED FOR PROCURING CLINICAL TRIAL SUPPLIES 118
TABLE 92 CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGY, BY REGION, 2020–2027 (USD MILLION) 118
TABLE 93 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 119
TABLE 94 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 119
TABLE 95 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 120
9.10 OTHER THERAPEUTIC AREAS 120
TABLE 96 CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2020–2027 (USD MILLION) 120
TABLE 97 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2020–2027 (USD MILLION) 121
TABLE 98 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2020–2027 (USD MILLION) 121
TABLE 99 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2020–2027 (USD MILLION) 122

10 CLINICAL TRIAL SUPPLIES MARKET, BY END USER 123

10.1 INTRODUCTION 124
TABLE 100 CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020–2027 (USD MILLION) 124
10.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 125
10.2.1 INCREASING R&D INVESTMENTS TO BOOST OUTSOURCING OF CLINICAL TRIAL SUPPLIES BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 125
TABLE 101 CLINICAL TRIAL SUPPLIES MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION) 125
TABLE 102 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 125
TABLE 103 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 126
TABLE 104 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 126
10.3 CONTRACT RESEARCH ORGANIZATIONS 127
10.3.1 INCREASING OUTSOURCING OF CLINICAL TRIALS TO DRIVE ADOPTION OF CLINICAL TRIAL SUPPLIES AMONG CROS 127
TABLE 105 CLINICAL TRIAL SUPPLIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2020–2027 (USD MILLION) 127
TABLE 106 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 127
TABLE 107 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 128
TABLE 108 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 128
10.4 MEDICAL DEVICE COMPANIES 129
10.4.1 INCREASING NUMBER OF TRIALS OF MEDICAL DEVICES TO DRIVE MARKET 129
TABLE 109 CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2020–2027 (USD MILLION) 129
TABLE 110 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 129
TABLE 111 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 130
TABLE 112 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 130

11 CLINICAL TRIAL SUPPLIES MARKET, BY REGION 131

11.1 INTRODUCTION 132
TABLE 113 CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020–2027 (USD MILLION) 133
11.2 NORTH AMERICA 133
TABLE 114 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 135
TABLE 115 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020–2027 (USD MILLION) 135
TABLE 116 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2020–2027 (USD MILLION) 136
TABLE 117 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 136
TABLE 118 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION) 137
TABLE 119 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020–2027 (USD MILLION) 137
11.2.1 US 138
11.2.1.1 Increasing R&D investments to drive market 138
TABLE 120 US: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020–2027 (USD MILLION) 138
TABLE 121 US: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2020–2027 (USD MILLION) 139
TABLE 122 US: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 139
TABLE 123 US: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION) 140
TABLE 124 US: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020–2027 (USD MILLION) 140
11.2.2 CANADA 141
11.2.2.1 Growing preference of pharmaceutical companies to conduct trials in Canada to favor market growth 141
TABLE 125 CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020–2027 (USD MILLION) 141
TABLE 126 CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2020–2027 (USD MILLION) 142
TABLE 127 CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 142
TABLE 128 CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION) 143
TABLE 129 CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020–2027 (USD MILLION) 143
11.3 EUROPE 144
TABLE 130 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 144
TABLE 131 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020–2027 (USD MILLION) 145
TABLE 132 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2020–2027 (USD MILLION) 145
TABLE 133 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 145
TABLE 134 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION) 146
TABLE 135 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020–2027 (USD MILLION) 146
11.3.1 GERMANY 147
11.3.1.1 Growing number of sponsored trials to boost demand for clinical trial supplies 147
TABLE 136 GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020–2027 (USD MILLION) 147
TABLE 137 GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2020–2027 (USD MILLION) 148
TABLE 138 GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 148
TABLE 139 GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION) 149
TABLE 140 GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020–2027 (USD MILLION) 149
11.3.2 UK 150
11.3.2.1 Government policies leading to costlier R&D and supply chain restrictions post Brexit to limit market growth 150
TABLE 141 UK: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020–2027 (USD MILLION) 150
TABLE 142 UK: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2020–2027 (USD MILLION) 151
TABLE 143 UK: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 151
TABLE 144 UK: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION) 152
TABLE 145 UK: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020–2027 (USD MILLION) 152
11.3.3 FRANCE 153
11.3.3.1 Presence of leading pharmaceutical companies to support market growth 153
TABLE 146 FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020–2027 (USD MILLION) 153
TABLE 147 FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2020–2027 (USD MILLION) 153
TABLE 148 FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 154
TABLE 149 FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION) 154
TABLE 150 FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020–2027 (USD MILLION) 155
11.3.4 ITALY 155
11.3.4.1 Increasing number of drug approvals to drive market for clinical trial supplies 155
TABLE 151 ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020–2027 (USD MILLION) 155
TABLE 152 ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2020–2027 (USD MILLION) 156
TABLE 153 ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 156
TABLE 154 ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION) 157
TABLE 155 ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020–2027 (USD MILLION) 157
11.3.5 SPAIN 158
11.3.5.1 Increasing biologics production to support market growth 158
TABLE 156 SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020–2027 (USD MILLION) 158
TABLE 157 SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2020–2027 (USD MILLION) 159
TABLE 158 SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 159
TABLE 159 SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION) 160
TABLE 160 SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020–2027 (USD MILLION) 160
11.3.6 SWITZERLAND 161
11.3.6.1 Growing R&D efforts to provide growth opportunities for clinical trial supplies market 161
TABLE 161 SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020–2027 (USD MILLION) 161
TABLE 162 SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2020–2027 (USD MILLION) 162
TABLE 163 SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 162
TABLE 164 SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION) 163
TABLE 165 SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020–2027 (USD MILLION) 163
11.3.7 REST OF EUROPE 164
TABLE 166 REST OF EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020–2027 (USD MILLION) 165
TABLE 167 REST OF EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2020–2027 (USD MILLION) 165
TABLE 168 REST OF EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 166
TABLE 169 REST OF EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION) 166
TABLE 170 REST OF EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020–2027 (USD MILLION) 167
11.4 ASIA PACIFIC 167
TABLE 171 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 169
TABLE 172 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020–2027 (USD MILLION) 169
TABLE 173 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2020–2027 (USD MILLION) 170
TABLE 174 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 170
TABLE 175 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION) 171
TABLE 176 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020–2027 (USD MILLION) 171
11.4.1 CHINA 172
11.4.1.1 Favorable government regulations to boost market growth 172
TABLE 177 CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020–2027 (USD MILLION) 172
TABLE 178 CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2020–2027 (USD MILLION) 173
TABLE 179 CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 173
TABLE 180 CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION) 174
TABLE 181 CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020–2027 (USD MILLION) 174
11.4.2 JAPAN 175
11.4.2.1 Government initiatives for drug innovation to support market growth 175
TABLE 182 JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020–2027 (USD MILLION) 175
TABLE 183 JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2020–2027 (USD MILLION) 176
TABLE 184 JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 176
TABLE 185 JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION) 177
TABLE 186 JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020–2027 (USD MILLION) 177
11.4.3 INDIA 178
11.4.3.1 Low manufacturing costs and skilled workforce—factors attracting outsourcing and investment to India 178
TABLE 187 INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020–2027 (USD MILLION) 178
TABLE 188 INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2020–2027 (USD MILLION) 179
TABLE 189 INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 179
TABLE 190 INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION) 180
TABLE 191 INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020–2027 (USD MILLION) 180
11.4.4 AUSTRALIA 181
11.4.4.1 Favorable location for drug discovery due to presence of many research institutes 181
TABLE 192 AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020–2027 (USD MILLION) 181
TABLE 193 AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2020–2027 (USD MILLION) 181
TABLE 194 AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 182
TABLE 195 AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION) 182
TABLE 196 AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020–2027 (USD MILLION) 183
11.4.5 SOUTH KOREA 183
11.4.5.1 Seoul among world’s largest clinical research centers 183
TABLE 197 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020–2027 (USD MILLION) 183
TABLE 198 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2020–2027 (USD MILLION) 184
TABLE 199 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 184
TABLE 200 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION) 185
TABLE 201 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020–2027 (USD MILLION) 185
11.4.6 SINGAPORE 186
11.4.6.1 Presence of world-class infrastructure to drive market 186
TABLE 202 SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020–2027 (USD MILLION) 186
TABLE 203 SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2020–2027 (USD MILLION) 186
TABLE 204 SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 187
TABLE 205 SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION) 187
TABLE 206 SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020–2027 (USD MILLION) 188
11.4.7 REST OF ASIA PACIFIC 188
TABLE 207 REST OF ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020–2027 (USD MILLION) 188
TABLE 208 REST OF ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2020–2027 (USD MILLION) 189
TABLE 209 REST OF ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 189
TABLE 210 REST OF ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION) 190
TABLE 211 REST OF ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020–2027 (USD MILLION) 190
11.5 REST OF THE WORLD 191
TABLE 212 REST OF THE WORLD: CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020–2027 (USD MILLION) 191
TABLE 213 REST OF THE WORLD: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020–2027 (USD MILLION) 192
TABLE 214 REST OF THE WORLD: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2020–2027 (USD MILLION) 192
TABLE 215 REST OF THE WORLD: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 193
TABLE 216 REST OF THE WORLD: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION) 193
TABLE 217 REST OF THE WORLD: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020–2027 (USD MILLION) 194
11.5.1 LATIN AMERICA 194
11.5.1.1 Growing R&D expenditure in pharmaceutical and biopharmaceutical sector to drive market 194
TABLE 218 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020–2027 (USD MILLION) 195
TABLE 219 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2020–2027 (USD MILLION) 195
TABLE 220 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 196
TABLE 221 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION) 196
TABLE 222 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020–2027 (USD MILLION) 197
11.5.2 MIDDLE EAST AND AFRICA 197
11.5.2.1 Growing presence of pharmaceutical companies to drive market 197
TABLE 223 MIDDLE EAST AND AFRICA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020–2027 (USD MILLION) 198
TABLE 224 MIDDLE EAST AND AFRICA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2020–2027 (USD MILLION) 198
TABLE 225 MIDDLE EAST AND AFRICA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2020–2027 (USD MILLION) 199
TABLE 226 MIDDLE EAST AND AFRICA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION) 199
TABLE 227 MIDDLE EAST AND AFRICA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020–2027 (USD MILLION) 200

12 COMPETITIVE LANDSCAPE 201

12.1 OVERVIEW 201
12.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS 202
FIGURE 27 CLINICAL TRIAL SUPPLIES MARKET: STRATEGIES ADOPTED BY KEY PLAYERS 202
12.3 REVENUE SHARE ANALYSIS OF KEY MARKET PLAYERS 203
FIGURE 28 KEY PLAYERS IN CLINICAL TRIAL SUPPLIES MARKET 203
12.4 MARKET SHARE ANALYSIS 204
FIGURE 29 CLINICAL TRIAL SUPPLIES MARKET SHARE, BY KEY PLAYER, 2021 204
12.5 COMPANY EVALUATION QUADRANT 205
12.5.1 STARS 206
12.5.2 EMERGING LEADERS 206
12.5.3 PERVASIVE PLAYERS 206
12.5.4 PARTICIPANTS 206
FIGURE 30 CLINICAL TRIAL SUPPLIES MARKET: COMPANY EVALUATION QUADRANT, 2021 207
12.6 COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES 208
12.6.1 PROGRESSIVE COMPANIES 208
12.6.2 STARTING BLOCKS 208
12.6.3 RESPONSIVE COMPANIES 208
12.6.4 DYNAMIC COMPANIES 208
FIGURE 31 CLINICAL TRIAL SUPPLIES MARKET: COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES, 2021 209
12.7 COMPETITIVE BENCHMARKING 210
TABLE 228 CLINICAL TRIAL SUPPLIES MARKET: DETAILED LIST OF KEY STARTUPS/SMES 210
12.7.1 FOOTPRINT ANALYSIS OF COMPANIES 211
TABLE 229 SERVICE FOOTPRINT OF COMPANIES 211
TABLE 230 REGIONAL FOOTPRINT OF COMPANIES 212
12.8 COMPETITIVE SCENARIO 213
TABLE 231 SERVICE LAUNCHES 213
TABLE 232 DEALS 214
TABLE 233 OTHER DEVELOPMENTS 215

13 COMPANY PROFILES 216

13.1 MAJOR PLAYERS 216
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
13.1.1 THERMO FISHER SCIENTIFIC 216
TABLE 234 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW 216
FIGURE 32 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021) 217
13.1.2 CATALENT, INC. 220
TABLE 235 CATALENT, INC.: BUSINESS OVERVIEW 220
FIGURE 33 CATALENT, INC.: COMPANY SNAPSHOT (2021) 221
13.1.3 MARKEN (SUBSIDIARY OF UPS) 224
TABLE 236 UPS: BUSINESS OVERVIEW 224
FIGURE 34 UPS: COMPANY SNAPSHOT (2021) 225
13.1.4 EUROFINS SCIENTIFIC 228
TABLE 237 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW 228
FIGURE 35 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2021) 228
13.1.5 PRA HEALTH SCIENCES (SUBSIDIARY OF ICON PLC) 230
TABLE 238 ICON PLC: BUSINESS OVERVIEW 230
FIGURE 36 ICON PLC: COMPANY SNAPSHOT (2021) 230
13.1.6 PAREXEL INTERNATIONAL CORPORATION 232
TABLE 239 PAREXEL INTERNATIONAL CORPORATION: BUSINESS OVERVIEW 232
13.1.7 BIOCAIR 234
TABLE 240 BIOCAIR: BUSINESS OVERVIEW 234
13.1.8 ALMAC GROUP 236
TABLE 241 ALMAC GROUP: BUSINESS OVERVIEW 236
13.1.9 PIRAMAL PHARMA SOLUTIONS 238
TABLE 242 PIRAMAL PHARMA SOLUTIONS: BUSINESS OVERVIEW 238
FIGURE 37 PIRAMAL PHARMA SOLUTIONS: COMPANY SNAPSHOT (2022) 239
13.1.10 INFOSYS 241
TABLE 243 INFOSYS: BUSINESS OVERVIEW 241
FIGURE 38 INFOSYS: COMPANY SNAPSHOT (2022) 242
13.1.11 PCI PHARMA SERVICES 243
TABLE 244 PCI PHARMA SERVICES: BUSINESS OVERVIEW 243
13.1.12 LIVEO RESEARCH 245
TABLE 245 LIVEO RESEARCH: BUSINESS OVERVIEW 245
13.1.13 CAPSUGEL (ACQUIRED BY LONZA) 246
TABLE 246 LONZA: BUSINESS OVERVIEW 246
FIGURE 39 LONZA: COMPANY SNAPSHOT (2021) 247
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
13.2 OTHER PLAYERS 249
13.2.1 OCT GROUP LLC 249
13.2.2 COREX LOGISTICS 250
13.2.3 ACNOS PHARMA GMBH 251
13.2.4 CLINICAL SERVICES INTERNATIONAL 251
13.2.5 KLIFO 252
13.2.6 CLINIGEN LIMITED 253
13.2.7 ANCILLARE, LP 254
13.2.8 N-SIDE 254
13.2.9 ADALLEN PHARMA 255
13.2.10 DURBIN 255
13.2.11 RECIPHARM AB 256
13.2.12 MOVIANTO 256
14 APPENDIX 257
14.1 DISCUSSION GUIDE 257
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 261
14.3 CUSTOMIZATION OPTIONS 263
14.4 RELATED REPORTS 263
14.5 AUTHOR DETAILS 264


    お問合せフォーム

    • レポートのタイトルは自動で入ります。
    • *のある項目は必須項目です。

    お名前*

    会社名*

    部署名

    メールアドレス*

    電話番号

    当ウェブサイトを知った経緯を教えてください。

    お問合せ内容

    株式会社SEMABIZ・ChosaReport.com プライバシーポリシー

    Eメールでのお問合せもお受けしております。
    下記アドレスへ“(at)”を“@”に変えてお送りください。通常1営業日以内にご返信いたします。
    crinquiry(at)chosareport.com